TY - JOUR T1 - Acute generalized exanthematous pustulosis during apalutamide treatment in a patient with prostate cancer. AU - Honda,Tomoko, AU - Tohi,Yoichiro, AU - Kaku,Yo, AU - Kimura,Nachino, AU - Kato,Takuma, AU - Haba,Reiji, AU - Dainichi,Teruki, AU - Sugimoto,Mikio, Y1 - 2022/08/16/ PY - 2022/06/20/received PY - 2022/08/06/accepted PY - 2022/11/7/entrez PY - 2022/11/8/pubmed PY - 2022/11/8/medline KW - acute generalized exanthematous pustulosis KW - adverse event KW - apalutamide KW - skin rash SP - 497 EP - 500 JF - IJU case reports JO - IJU Case Rep VL - 5 IS - 6 N2 - Introduction: Acute generalized exanthematous pustulosis is a type of severe cutaneous drug adverse reaction. While apalutamide is known for its high incidence of cutaneous adverse events, it remains unknown whether acute generalized exanthematous pustulosis can develop during apalutamide treatment. Case presentation: A 72-year-old man with metastatic castration-sensitive prostate cancer developed small erythema on the face and trunk after 41 days of apalutamide treatment. Three days later, apalutamide was discontinued. However, 9 days after the discontinuation of apalutamide, the patient had a high fever with hemodynamic instability and showed diffuse erythema throughout the body with numerous small pustules. Skin biopsy revealed subcorneal and intraepidermal pustules admixed with many eosinophils, which led to the diagnosis of acute generalized exanthematous pustulosis. The skin rash improved in 14 days with systemic corticosteroid administration. Conclusion: We present the first case of a skin rash with clinical features of acute generalized exanthematous pustulosis during apalutamide treatment. SN - 2577-171X UR - https://www.unboundmedicine.com/medline/citation/36341202/Acute_generalized_exanthematous_pustulosis_during_apalutamide_treatment_in_a_patient_with_prostate_cancer_ DB - PRIME DP - Unbound Medicine ER -